Navigation Links
Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Date:7/12/2011

SAN DIEGO, July 12, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

The randomized, double-blind and placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 mg and 0.2 mg single doses of APD811. The trial evaluated 32 healthy volunteers in four cohorts of eight participants each – six randomized to APD811 and two to placebo. APD811 was rapidly absorbed and demonstrated dose-proportional pharmacokinetic exposure over the tested dose range. The terminal half-life was approximately 20 hours.

The most frequent treatment-emergent adverse events were headache, vomiting, nausea, jaw pain and flushing. Dose-limiting adverse events of nausea and vomiting occurred at the 0.2 mg dose. As compared to placebo, heart rate trended higher at the 0.05 mg, 0.1 mg and 0.2 mg doses and the corrected QT (QTc) interval trended higher at the 0.1 mg and 0.2 mg doses. Arena believes the QTc observation is not supported by preclinical data and will further evaluate this in future studies. No serious adverse events were reported.

"We are encouraged by the results of this early stage clinical trial that suggest APD811 has the potential for once-daily, oral dosing, and our next step will be to evaluate the safety, tolerability and pharmacokinetics of multiple dosing and the optimal titration schedule in a Phase 1b trial," said William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer. "The development of APD811 is the result of Arena's continuing commitment to advance our diverse research and development pipeline."

About Pulmonary Arterial Hypertension (PAH)PAH is a progressi
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
2. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
3. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
6. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
8. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
9. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
11. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... NESS ZIONA, Israel , ... today announced that results from a phase I study ... study in advanced Parkinson,s patients, of ND0612, were presented ... Movement Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug ... (SC) delivery patch that would maintain constant levodopa plasma ...
(Date:6/19/2013)... 19, 2013   Life Technologies Corporation ... agreement granting Suzhou Ribo Life Sciences (Ribo) the ... in China using Life,s ... siRNA molecules in combination with Invivofectamine® Rx to ... diseases with high unmet medical need in the ...
(Date:6/19/2013)... , 19. Juni 2013 /PRNewswire/ ... dass mit der Entwicklung von SCS ... Schritt in der Beschichtung mit Parylene ... Vorteile von biokompatiblem Parylene mit antimikrobiellen ... Beseitigung schädlicher Mikroorganismen auf beschichteten medizinischen ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2
... HARBIN, China , May 18 /PRNewswire-Asia-FirstCall/ -- ... (Nasdaq: CSKI ), a leading fully,integrated pharmaceutical company producing ... today announced record financial results,for the first quarter of 2010. ... Form 10-K for 2009. , , First ...
... HARBIN, China , May 18 ... Board: WKBT) ("Weikang" or the,"Company"), a leading developer, manufacturer ... and other health,and nutritional products in the People,s ... the first quarter of fiscal year 2010 ended on ...
Cached Medicine Technology:China Sky One Medical Announces First Quarter 2010 Results 2China Sky One Medical Announces First Quarter 2010 Results 3China Sky One Medical Announces First Quarter 2010 Results 4China Sky One Medical Announces First Quarter 2010 Results 5China Sky One Medical Announces First Quarter 2010 Results 6China Sky One Medical Announces First Quarter 2010 Results 7China Sky One Medical Announces First Quarter 2010 Results 8China Sky One Medical Announces First Quarter 2010 Results 9China Sky One Medical Announces First Quarter 2010 Results 10China Sky One Medical Announces First Quarter 2010 Results 11China Sky One Medical Announces First Quarter 2010 Results 12China Sky One Medical Announces First Quarter 2010 Results 13China Sky One Medical Announces First Quarter 2010 Results 14Weikang Bio-Technology Reports First Quarter 2010 Financial Results 2Weikang Bio-Technology Reports First Quarter 2010 Financial Results 3Weikang Bio-Technology Reports First Quarter 2010 Financial Results 4Weikang Bio-Technology Reports First Quarter 2010 Financial Results 5Weikang Bio-Technology Reports First Quarter 2010 Financial Results 6Weikang Bio-Technology Reports First Quarter 2010 Financial Results 7Weikang Bio-Technology Reports First Quarter 2010 Financial Results 8Weikang Bio-Technology Reports First Quarter 2010 Financial Results 9Weikang Bio-Technology Reports First Quarter 2010 Financial Results 10Weikang Bio-Technology Reports First Quarter 2010 Financial Results 11
(Date:6/20/2013)... Dr. Ramtin Kassir is one of ... and NYC and a top cosmetic surgeon in ... is to provide individualized care for a broad spectrum of ... surgeon is partnering with the new and emerging business consultancy ... its specialized needs. , "We are partnering with Tom and ...
(Date:6/20/2013)... June 20, 2013 Volume based manufacturing ... dramatically reduce the retail pricing of both it's WHEY ... replacement products. , Premier Natural Health’s whey protein ... food sources and are formulated to help maintain healthy ... intake and slow the aging process. , Ideal ...
(Date:6/20/2013)... Sydney, Australia (PRWEB) June 20, 2013 ... , research was presented recently, that can show similarities ... food. This could explain the current global obesity ... be addicted to food just as one can be ... Neuroscience and Applied Cognitive Science at the University of ...
(Date:6/19/2013)... (PRWEB) June 20, 2013 With the ... has put together their winter season Santiago day ... adventure day trips in and around Santiago this season, ... into Chile's Central Andes for backcountry skiing, challenging rock ... those who have always dreamed of skiing in ...
(Date:6/19/2013)... York, NY (PRWEB) June 19, 2013 The ... American bands in the country and folk music genre. This ... Brown (who is the lead vocals and guitarist), Jimmy De ... Hopkins (the bass guitarist and in vocals), Coy Bowles (guitarist ... de los Reyes (percussionist). The band was formed in ...
Breaking Medicine News(10 mins):Health News:Celebrity Plastic Surgeon Dr. Kassir Teams Up With X Factor Selling Systems to Enhance Patient Experience 2Health News:Premier Natural Health, a Leading Provider of Natural Food Products and Herbal Solutions, Reduces Prices On Its Popular Whey Protein Product 2Health News:Premier Natural Health, a Leading Provider of Natural Food Products and Herbal Solutions, Reduces Prices On Its Popular Whey Protein Product 3Health News:Research Suggests That Unhealthy Food Addiction Could Explain Global Obesity Epidemic 2Health News:Chile Montaña Announces Winter Season Santiago Day Trips 2Health News:Chile Montaña Announces Winter Season Santiago Day Trips 3Health News:Zac Brown Band Tickets for Raleigh, Columbia, Darien Center, Gilford, Minneapolis, Holmdel, Pittsburgh, Camden, Atlanta, Boston, Bethel, Toronto & Hartford Now Available 2
... ISTA,Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced ... 30, 2008, after the U.S. markets,close. ISTA will host ... results at 4:30 p.m. Eastern Time on April 30., ... Canadian participants may,dial 866-362-5158; international participants may dial 617-597-5397. ...
... Camp-based therapy proved more beneficial than individual grief counseling, ... Children who experience the unexpected death of a parent ... (PTSD), a finding that has major implications for helping ... researchers. , "Often children who have lost a parent ...
... melanomas die at nearly twice the rate of people with ... researchers at the University of North Carolina at Chapel Hill ... the U.S. confirms that survival rates differ depending on where ... die at a rate 1.84 times higher than those with ...
... millimeters in diameter appear more likely to be melanomas ... April issue of Archives of Dermatology, one of the ... currently used by dermatologists to screen for melanoma are ... screen for melanoma, according to background information in the ...
... Howard G. Smith,announces a May 12, 2008, deadline to ... action lawsuit filed on behalf of all persons who,purchased ... the "Company") (Nasdaq: VRTX ) between June 12, ... shareholder lawsuit,is pending in the United States District Court ...
... Decisions on Bottom Line Return at 3rd Annual ... Pharmaceutical Market Research Summit, NEW ... the pharmaceutical analytics company Eularis, will be,delivering a presentation on ... Research and Decisions on Bottom Line Return., ...
Cached Medicine News:Health News:Treating PTSD Helps Kids Deal With Loss 2Health News:Most lethal melanomas are on scalp and neck 2Health News:Larger skin lesions appear more likely to be melanomas 2Health News:Eularis to Address Making the Right Research Decision for ROI 2
Delicate side cutting wire cutter with carbide inserts....
Curved osteotome for bone removing....
... core product. It is created using the Panoramic200 ... for the screening of eye and non-eye diseases ... examination basis and is non-reimbursable. The optomap provides ... of the patients retina which is viewed on-screen ...
... The Pulse CDC Compact Cardiac Digital Camera is ... an open, patient-friendly gantry, and provides full sized ... camera into your clinic you need a flexible ... layout. Find out how the Pulse reduces ...
Medicine Products: